JAKAFI (ruxolitinib phosphate)
ANTINEOPLASTIC - JANUS KINASE (JAK) INHIBITORS · POLYCYTHEMIA VERA ·+3
Incyte Corporation
Drug class
Antineoplastic - Janus Kinase (JAK) Inhibitors
Antineoplastic Janus kinase (JAK) inhibitors are targeted small-molecule therapeutics that disrupt the intracellular JAK-STAT signaling pathway to suppress malignant cell growth and excessive cytokine activation. Read more about Antineoplastic - Janus Kinase (JAK) Inhibitors
6 drugs in this class 5 manufacturers
Drugs in Antineoplastic - Janus Kinase (JAK) Inhibitors
VONJO (pacritinib citrate)
ANTINEOPLASTIC - JANUS KINASE (JAK) INHIBITORS · MYELOFIBROSIS
CTI BIOPHARMA C
INREBIC (fedratinib dihydrochloride)
ANTINEOPLASTIC - JANUS KINASE (JAK) INHIBITORS · MYELOFIBROSIS
CELGENE/BMS
OJJAARA (momelotinib dihydrochloride)
ANTINEOPLASTIC - JANUS KINASE (JAK) INHIBITORS · MYELOFIBROSIS
GSK
VONJO (pacritinib citrate)
ANTINEOPLASTIC - JANUS KINASE (JAK) INHIBITORS · MYELOFIBROSIS
BIOVITRUM
JAKAFI XR (ruxolitinib phosphate)
ANTINEOPLASTIC - JANUS KINASE (JAK) INHIBITORS · POLYCYTHEMIA VERA ·+3
Incyte Corporation
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - Janus Kinase (JAK) Inhibitors preselected. Add indication or manufacturer filters there.
Antineoplastic Janus kinase (JAK) inhibitors are targeted small-molecule therapeutics that disrupt the intracellular JAK-STAT signaling pathway to suppress malignant cell growth and excessive cytokine activation.
By selectively or broadly inhibiting Janus kinase enzymes (primarily JAK1 and JAK2), these agents downregulate downstream signal transducers and activators of transcription, thereby inhibiting abnormal cellular proliferation and inducing apoptosis.
This drug class is primarily indicated for hematologic malignancies and myeloproliferative neoplasms, notably intermediate- or high-risk myelofibrosis and hydroxyurea-resistant or intolerant polycythemia vera.
Additionally, certain agents within the class are utilized to manage acute and chronic graft-versus-host disease in stem cell transplant recipients.
-
nih.gov
Antineoplastic Janus kinase (JAK) inhibitors are targeted small-molecule therapeutics that disrupt the intracellular JAK-STAT signaling pathway to suppress malignant cell growth and excessive cytokine activation
-
cancer.gov
Antineoplastic Janus kinase (JAK) inhibitors are targeted small-molecule therapeutics that disrupt the intracellular JAK-STAT signaling pathway to suppress malignant cell growth and excessive cytokine activation By selectively or broadly inhibiting Janus kinase enzymes (primarily JAK1 and JAK2), these agents downregulate downstream signal transducers and activators of transcription, thereby inhibiting abnormal cellular proliferation and inducing apoptosis
-
cancer.gov
By selectively or broadly inhibiting Janus kinase enzymes (primarily JAK1 and JAK2), these agents downregulate downstream signal transducers and activators of transcription, thereby inhibiting abnormal cellular proliferation and inducing apoptosis
-
nih.gov
By selectively or broadly inhibiting Janus kinase enzymes (primarily JAK1 and JAK2), these agents downregulate downstream signal transducers and activators of transcription, thereby inhibiting abnormal cellular proliferation and inducing apoptosis
-
rxlist.com
Additionally, certain agents within the class are utilized to manage acute and chronic graft-versus-host disease in stem cell transplant recipients
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.